



REVIEW

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]

Mari Iwasaki¹, Yasutada Akiba^{1,2}, Jonathan D Kaunitz ^{1,3}

¹Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA

²Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

³Departments of Medicine and Surgery, UCLA School of Medicine, Los Angeles, CA, USA

v1 **First published:** 12 Sep 2019, 8(F1000 Faculty Rev):1629 (<https://doi.org/10.12688/f1000research.18039.1>)
Latest published: 12 Sep 2019, 8(F1000 Faculty Rev):1629 (<https://doi.org/10.12688/f1000research.18039.1>)

Abstract

Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions that in turn regulate ion secretion, nutrient absorption, gut motility, glycemic control, carcinogenesis, immune responses, and circadian rhythms. Genetic ablation of this peptide and its receptors in mice also provides new insights into the contribution of VIP towards physiological signaling and the pathogenesis of related diseases. Here, we discuss the impact of VIP on gastrointestinal function and diseases based on recent findings, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.

Keywords

vasoactive intestinal peptide, VIP, VPAC1, VPAC2, vasodilation, neuropeptide, gastrointestinal, gastrointestinal tract, gastrointestinal secretion, mast cells, gastrointestinal motility, colitis, functional bowel syndromes

Open Peer Review

Reviewer Status 

	Invited Reviewers			
	1	2	3	4
version 1 published 12 Sep 2019				

F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

- 1 **Mario Delgado**, Institute of Parasitology and Biomedicine Lopez-Neyra, Consejo Superior Investigaciones Cientificas, Granada, Spain
- 2 **Peter Holzer**, Medical University of Graz, Graz, Austria
- 3 **Michael Camilleri**, Mayo Clinic, Rochester, USA
- 4 **Pradeep Dudeja**, University of Illinois at Chicago, Chicago, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Jonathan D Kaunitz (jake@ucla.edu)

Author roles: **Iwasaki M:** Conceptualization, Writing – Original Draft Preparation; **Akiba Y:** Conceptualization, Resources, Supervision, Writing – Review & Editing; **Kaunitz JD:** Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by a Department of Veterans Affairs Merit Review Award.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Iwasaki M *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions.

How to cite this article: Iwasaki M, Akiba Y and Kaunitz JD. **Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]** F1000Research 2019, 8(F1000 Faculty Rev):1629 (<https://doi.org/10.12688/f1000research.18039.1>)

First published: 12 Sep 2019, 8(F1000 Faculty Rev):1629 (<https://doi.org/10.12688/f1000research.18039.1>)

Introduction

Vasoactive intestinal peptide (VIP) is a 28-residue amino acid peptide first characterized in 1970 that was initially isolated from porcine duodenum¹. A member of the secretin/glucagon hormone superfamily^{1,2}, VIP is evolutionarily well conserved with sequence similarity among fish, frogs, and humans³; among mammals, except for guinea pigs and chickens⁴, the sequence similarity is at least 85%⁵. VIP was initially discovered owing to its potent vasodilatory effects (as its name implies). VIP is widely distributed in the central and peripheral nervous system as well as in the digestive, respiratory, reproductive, and cardiovascular systems as a neurotransmitter and neuroendocrine releasing factor^{5,6}. These effects contribute to an extensive range of physiological and pathological processes related to development, growth, and the control of neuronal, epithelial, and endocrine cell function. VIP has also been implicated in the regulation of carcinogenesis, immune responses, and circadian rhythms⁷. Here, we focus on current findings related to VIP and its signals in the gastrointestinal (GI) tract with regard to its effects on secretion, intestinal barrier function, and mucosal immunology.

Historical background

In the late 1960s, Dr. Sami I. Said at the Medical College of Virginia reported that systemic injection of extracts of mammalian lungs produced generalized vasodilation and hypotension. Together with Dr. Viktor Mutt from Karolinska University, Stockholm, Sweden, Dr. Said turned his search from the lung to duodenal extracts, which were more readily available, based on the premise that the same peptide might be present in other organs. They soon discovered that peptide fractions from porcine duodenum indeed contained a component with vasodilatory activity⁸, supporting Bayliss and Starling's assumption (made in 1902 during their discovery of secretin) that a "vasodepressor principle" was present in intestinal extracts⁹.

A few years later, VIP was identified in the central and peripheral nervous systems¹⁰ and has since been recognized as a

widely distributed neuropeptide, acting as a neurotransmitter or neuromodulator in many organs and tissues, including the heart, lung, thyroid gland, kidney, immune system, urinary tract, and genital organs³. VIP's presence across numerous locations is related to its participation in a vast number of biological events¹¹.

Structure and classification

The three-dimensional structure of VIP is similar to that of other members of the glucagon and secretin family², in which the structure, function, and signaling activity of pituitary adenyl cyclase-activating peptide (PACAP) is the most closely related peptide to VIP, sharing 68% sequence homology¹¹. VIP is cleaved from a ~9 kb precursor molecule, prepro-VIP, located in the chromosomal region 6q24 containing seven exons⁶, each encoding a functional domain. The signal peptidase located in the endoplasmic reticulum cleaves the signal peptide from the 170-amino-acid prepro-VIP, then forms a 149-amino-acid precursor peptide termed pro-VIP, which is then cleaved by prohormone convertases to a form of VIP precursor containing the internal cleave-amidation site Gly-Lys-Arg (GKR) (VIP-GKR; prepro-VIP₁₂₅₋₁₅₅)¹² (Figure 1). The KR residues of VIP-GKR are then cleaved by carboxypeptidase B-like enzymes to VIP-G¹³, which is then metabolized by peptidyl-glycine alpha-amidating monooxygenase (PAM) to VIP, which has an amidated C-terminus¹¹ (Figure 1). Prepro-VIP also contains a bioactive hormone, peptide histidine methionine (PHM) in humans or peptide histidine isoleucine (PHI) in other mammals; PHM/PHI are less potent than VIP¹⁴. VIP varies its conformation depending on the environment. Most notably, its α -helical forms are present when VIP is in the presence of an anionic lipid bilayer or liposomes when bound to receptors⁵.

VIP and its receptors

The two receptors that recognize VIP, termed VPAC1 and VPAC2, are class B of G-protein-coupled receptors (GPCRs), also known as the secretin receptor family, which includes receptors




Figure 1. Processing of prepro-VIP to VIP. PHI, peptide histidine isoleucine; PHM, peptide histidine methionine; VIP, vasoactive intestinal peptide; VIP-GKR, VIP precursor containing the internal cleave-amidation site Gly-Lys-Arg.

for VIP, PACAP, secretin, glucagon, glucagon-like peptide (GLP)-1 and -2, calcitonin, gastric inhibitory peptide (GIP), corticotropin-releasing factor (CRF)-1 and -2, and parathyroid hormone (PTH). VPAC1 and VPAC2 are activated by VIP and PACAP¹⁵, whereas PACAP has its own specific receptor, named PAC1, for which VIP has very low affinity¹⁶. Through these receptors, VIP can mediate an extensive number of GI functions such as regulating gastric acid secretion, intestinal anion secretion, enzyme release from the pancreas, cellular motility, vasodilation, and intestinal contractility¹⁷⁻¹⁹. The localization of VIP, VPAC1, and VPAC2 is closely related to their physiological and pathological functions, which are also discussed under the heading “Functions in the GI tract”.

Localization of VIP

VIP is produced in the neurons in the central and peripheral nervous systems. VIP is mainly localized in the myenteric and submucosal neurons and nerve terminals in the GI tract^{20,21}. Endogenous VIP is released by numerous stimuli such as acetylcholine (ACh)²², ATP²³, serotonin (5-HT)²⁴, substance P (SP)²⁵, GLP-2²⁶, and xenin-25²⁷ from at least two populations of VIP-positive nerves: cholinergic and non-cholinergic VIP-releasing nerves. In guinea pig small intestine, most VIP-positive nerves in the mucosa and submucosa are non-cholinergic secretomotor neurons²⁸ and well colocalized with neuronal nitric oxide synthase (nNOS) in human colonic circular muscles²⁹.

VIP is also expressed in immune cells, such as activated T cells^{30,31}, and therefore present in lymphoid tissues including Peyer's patches, the spleen, and lymph nodes, in addition to the VIP-ergic innervation in lymphoid tissues. VIP is produced by immune cells including T cells, B cells, mast cells, and eosinophils stimulated by lipopolysaccharide (LPS) and proinflammatory cytokines including tumor necrosis factor (TNF)- α , interleukin (IL)-6, and IL-1 β ³².

Interestingly, VIP-positive parasympathetic nerves are present in the pancreatic islet, and vagal stimulation increases the release of VIP in the canine islet³³. PACAP is also present in the pancreatic islet and amplifies the glucose-induced insulin secretion³⁴. These findings suggest that VIP and PACAP modulate glucose-induced insulin secretion, similar to the incretins GLP-1 and GIP.

Phenotype of VIP deficiency

The VIP knockout (KO) mouse exhibits phenotypes, including disturbances of circadian rhythm³⁵, inflammatory responses^{36,37}, and metabolism³⁸. In the GI tract, VIP KO mice exhibit abnormalities of the small intestine rather than of the colon, with increased villus length, reduced mucus secretion, thickened muscle layers, and impaired GI transit³⁹. Furthermore, VIP deficiency increases small intestinal crypt depth with increased crypt cell proliferation, which is not reversible with exogenous VIP treatment⁴⁰. In contrast, the colon of VIP KO mice exhibits decreased crypt height with reduced cell proliferation and increased apoptosis, reduced mucus production, and increased fluorescein-dextran 4000 (FD4) permeability³⁷.

Interestingly, exogenous VIP treatment of VIP KO mice restores these changes in the colon³⁷ but does not reverse the mucosal changes in the small intestine as mentioned above⁴⁰. Therefore, the physiological and pathological contributions of VIP towards growth and development may differ among GI segments.

VPAC1 in the GI tract

VPAC1, for which no receptor splice variant is known, was first isolated and identified from the rat lung and later identified in human tissues. The majority of VIP actions are mediated through the VPAC1 receptor expressed on the epithelial cells, cholinergic excitatory motor neurons innervating longitudinal muscles, cholinergic secretomotor neurons, and mucosal mast cells^{41,42}. Selective agonists and antagonists have been synthesized for its anticipated experimental and clinical use^{15,43}.

VPAC1 in mice and humans is predominantly expressed in the colon relative to the small intestine⁴⁴ and is predominantly expressed in the mucosa and submucosa compared to the muscle layers in rat ileum²⁷, suggesting that VIP effects on epithelial functions, including ion transport, mucus secretion, tight junction protein expression, and cell proliferation, are mainly mediated via VPAC1 activation. VPAC1 localization in the epithelial cells is thought to be on the basolateral membranes, since serosally applied VIP increases electrogenic anion secretion in the small and large intestine^{45,46}. Nevertheless, the exact localization of VPAC1 on the basolateral membranes of epithelial cells has not been reported, whereas VPAC1 was immunolocalized to the apical membranes of mouse and human colonic epithelial cells⁴⁴. Functional studies of VPAC1 activity through the apical membranes of colonocytes are awaited.

VPAC1 is constitutively expressed on T cells and macrophages but less on dendritic cells, mast cells, and neutrophils¹¹. VIP differentially induces histamine release from mast cells in that peritoneal mast cells respond to VIP more than intestinal mucosal mast cells⁴⁷, likely corresponding to the VPAC1 activation on mast cells.

VPAC1 KO mice exhibit impaired neonatal growth and increased post-weaning death due to intestinal obstruction and hypoglycemia, histologically with increased mucosal cell proliferation, bowel wall thickening, and smaller pancreatic islet size⁴⁸, suggesting that VPAC1 is essential for the normal development of the intestinal tract and the endocrine pancreas.

VPAC2 in the GI tract

VPAC2 receptors are predominantly expressed in smooth muscles throughout the GI tract and in vascular smooth muscles in humans⁴⁹ and mice⁵⁰. Interestingly, thyroid follicles also show VPAC2-specific binding⁵⁰. Although VPAC2 expression in nerves and follicles in the thyroid and parathyroid is reported⁵¹, there is no evidence of thyroid or PTH release by VIP or PACAP, whereas VIP increases thyroid blood flow⁵². VPAC2

is also expressed at a high level in pancreatic β cells⁵³. VPAC2 is upregulated in activated macrophages induced by LPS and T helper (Th) cells induced by IL-4 stimulation¹¹.

VPAC2 KO mice showed significant growth impairment, decreased fat mass and increased lean mass, increased insulin sensitivity, and increased basal metabolic rate with lower serum thyroid hormone (free T3) levels and lower serum insulin-like growth factor-1 only in young females⁵⁴. Another group reported that VPAC2 KO mice exhibited impaired circadian rhythms with reduced metabolic rates and disrupted feeding rhythm⁵⁵. However, the basal phenotype of the GI tract of VPAC2 KO mice has not been reported, although VPAC2 KO mice exhibit enhanced susceptibility to chemically induced colitis⁵⁶. Predominant VPAC2 expression in GI smooth muscles predicts impaired intestinal motility in VPAC2 KO mice, since VIP KO mice show delayed intestinal transit³⁹. Similarly, although chemically induced colitis was less severe in PACAP KO mice⁵⁷, the intestinal phenotype of PACAP KO mice has not yet been reported.

Functions in the GI tract

Prosecretory action of VIP

VIP released from enteric nerves stimulates anion secretion from the enterocytes via G_s -coupled VPAC1 activation⁵⁸, followed by adenylyl cyclase activation, increased intracellular cAMP, protein kinase A (PKA) activation, and cystic fibrosis transmembrane conductance regulator (CFTR) activation^{46,59}. In the duodenum, exogenous VIP increases protective HCO_3^- secretion via a CFTR-dependent pathway⁴⁶. In the ileum and colon, VIP increases electrogenic Cl^- and HCO_3^- secretion^{27,45,59}. VIP also increases Cl^- secretion in porcine gallbladder⁶⁰ and increases porcine pancreatic fluid and HCO_3^- secretion⁶¹.

Hypersecretion of VIP leads to severe watery diarrhea in humans. VIP-secreting endocrine tumors termed VIPomas are the best-characterized models of increased endogenous VIP secretion. Hypersecretion of VIP by this ectopic tumor causes large-volume watery diarrhea, hypokalemia, and achlorhydria known as pancreatic cholera, the Verner–Morrison syndrome, or the WDHA syndrome⁶², due to the action of VIP on VPAC1 receptors in the intestinal mucosa that increases Cl^- and water movement into the intestinal lumen⁵⁸. One case report shows that a patient with WDHA syndrome was successfully treated with octreotide, a somatostatin analog, and octreotide-based radionuclide scanning localized the pancreatic tumor, which was VIP and VPAC1 positive by immunohistochemistry⁶³, suggesting that hypersecretion of VIP from a VIPoma affects tumor growth and that VIP release is modified via VPAC1 activation with positive or negative feedback. VIP and PACAP also stimulate amylase secretion from pancreatic acini of rat and guinea pig via both VPAC1 and VPAC2 activation⁶⁴.

Vasodilatory action of VIP

VIP acts as a potent vasodilator. Close intra-arterial infusion of VIP increases blood flow in the gastric, small intestinal, and colonic mucosa in cats and rats^{65,66}. In contrast, systemic

intravenous (IV) infusion of VIP decreases mucosal blood flow in the rat duodenum, accompanied by systemic hypotension⁶⁷. Vasodilatory effects of VIP are mediated via VPAC1 activation on endothelial cells, followed by release of NO, and via VPAC2 activation on vascular smooth muscle cells in the porcine basilar arteries⁶⁸. Although the detailed mechanisms of VIP-induced vasodilation in the GI mucosa are not fully understood, the basilar artery study suggests that VIP-induced mucosal hyperemia may be mediated via direct activation of vascular smooth muscle VPAC2 and indirectly via VPAC1 activation with NO release. Close intra-arterial infusion of ATP increases gastric and small intestinal mucosal blood flow concomitant with parallel release of VIP⁶⁹, suggesting that neural ATP release and P2 receptor activation on VIP-ergic nerves may induce vasodilation via VIP release. VIP also inhibits lymphatic vessel pumping via VPAC2 activation on lymphatic smooth muscle cells⁷⁰, suggesting that locally released VIP modulates lymph drainage and is implicated in inflammation-associated edema.

Smooth muscle contraction and relaxation by VIP

VIP contracts and relaxes GI smooth muscles. Rabbit and guinea pig gastric and tænia coli smooth muscle cells express only VPAC2, not VPAC1 or PAC1⁷¹. Autoradiography using a VPAC2-selective agonist demonstrated that VPAC2 is predominantly expressed on smooth muscle cells of the vasculature of the smooth muscle layers of the GI tract⁵⁰. Human gastric smooth muscle cells are relaxed in response to VIP, most probably via VPAC2 activation⁷². Selective VPAC2 agonists, not VPAC1 agonists, relax pre-contracted longitudinal muscles of rat fundic stomach⁷³. In contrast, VPAC1 is expressed on the myenteric neurons colocalized with choline acetyltransferase (ChAT), and VIP contracts longitudinal muscles of guinea pig jejunum via muscarinic receptor and VPAC1 activation⁴¹, suggesting that VPAC1 activation releases ACh from secretomotor neurons. PACAP-induced, non-adrenergic, non-cholinergic (NANC) relaxation of longitudinal muscle of the proximal colon is markedly reduced in PAC1 KO mice⁷⁴, suggesting that PAC1 expressed on NANC nerves mediates PACAP-induced relaxation and PACAP may also directly activate VPAC2 on smooth muscle cells, and then induce relaxation.

Gastric inhibitory action of VIP

VIP inhibits gastric acid secretion via inhibition of gastrin release in dogs^{75,76}. PACAP also inhibits gastric acid secretion stimulated by pentagastrin and histamine⁷⁷. A study using isolated histamine-containing enterochromaffin-like (ECL) cells and somatostatin (SST)-containing D cells demonstrate that PAC1 is expressed on ECL cells and PACAP, not VIP, increases histamine release from ECL cells, whereas D cells release SST in response to both VIP and PACAP⁷⁸. Furthermore, SST blockade with specific antibodies enhanced PACAP-induced gastric acid secretion in rats *in vivo*⁷⁸. VIP-positive and PACAP-positive nerves are present in the gastric mucosa^{79,80}. Fluorescent protein-tagged reporter mice for SST demonstrate that purified D cells express VPAC1 and release SST in response to VIP⁸¹. These results suggest that VIP inhibits gastric acid secretion via VPAC1 activation on D cells and SST release, whereas PACAP stimulates acid secretion

via histamine release from ECL cells, parallel with SST release from D cells via VPAC1 activation.

VIP effects on epithelial paracellular permeability

VIP modulates epithelial paracellular permeability via regulation of the expression and function of epithelial tight junction proteins. VIPergic pathways increase the expression of the tight junction protein zonula occludens-1 (ZO-1) in human polarized colonic epithelial monolayers co-cultured with human submucosa containing the submucosal plexus, associated with reduced epithelial paracellular permeability⁸². VIP also ameliorates bacterial infection-induced intestinal barrier disruption by preventing the translocation of tight junction proteins ZO-1, occludin, and claudin-3 in a *Citrobacter rodentium*-induced colitis model⁸³.

Mucosal inflammation increases epithelial paracellular permeability primarily due to the alteration of the epithelial tight junction complex by TNF- α and interferon (IFN)- γ derived from activated macrophages and T cells⁸⁴. Since VIP and PACAP equally reduce TNF- α release from activated macrophages induced by LPS⁸⁵, and since VPAC2 reduces the activation of inflammatory cells⁸⁶, VIP-VPAC2 signaling may modify the epithelial paracellular permeability changes during intestinal inflammation.

VIP and irritable bowel syndrome

Irritable bowel syndrome (IBS) is a chronic symptomatic GI disorder characterized by abdominal pain with altered bowel function, typically constipation and/or diarrhea. IBS with diarrhea (IBS-D) correlates with increased mast cell function and VIP release. Mast cell number and tissue immunoreactivity for substance P and VIP are greater in IBS-D patients, especially in women⁸⁷. A recent study shows that female IBS patients have higher plasma VIP and higher mast cell tryptase content and mast cell number in colonic biopsies compared to data from controls⁸⁸. Furthermore, colonic biopsies show greater transcellular bacterial passage and a higher percentage of mast cells that express VPAC1 than do biopsies from controls. Bacterial passage through the colonic biopsies was inhibitable with anti-VPAC antibodies or with the mast cell stabilizer ketotifen⁸⁸. These data suggest that mast cells and VIP are key modifiers of bacterial translocation in the colonic mucosa of IBS patients. However, the observations of colonic mucosal barrier function and the roles of VIP and mast cells in colonic biopsies require confirmation in patients with IBS *in vivo*.

Stress is a key factor in IBS pathogenesis. One of the stress-induced hormones is corticotropin-releasing factor (CRF), which is an important bioactive molecule not only in the central nervous system but also in the peripheral enteric nervous system. Stress-induced defecation and diarrhea in rodents is induced by peripheral administration of CRF via CRF1 receptor activation⁸⁹. Peripheral CRF-induced defecation and diarrhea involves VIP signals via the activation of CRF1-positive VIPergic submucosal neurons⁹⁰, suggesting that stress-induced diarrhea observed in IBS-D patients can

be treated with VPAC1 antagonists that reduce the volume and frequency of bowel movements⁸⁸.

VIP and immunity

The GI mucosa is the largest immune system in the body, likely owing to its status as the largest area of interface with the outside world. The GI tract contains luminal microbiota and numerous immune cells in the epithelium, lamina propria mucosa, and lymphoid follicles⁹¹. VIP, as an anti-inflammatory mediator, downregulates the abundance of pro-inflammatory cytokines and mediators such as TNF- α , IL-6, IL-12, nitric oxide, and chemokines⁹². VIP, which is also produced by type 2 lymphocytes (Th2), could also be classified as a Th2 cytokine^{31,92}. The potent anti-inflammatory effects of VIP may result from its promotion of Th cell differentiation toward a “Th2” phenotype¹¹. Moreover, VIP also increases regulatory T cell production while inhibiting macrophage pro-inflammatory actions, all contributing to its anti-inflammatory effects.

VIP maintains immunological tolerance and homeostasis in the gut primarily by regulation of T cell responses and Toll-like receptor (TLR)-mediated innate immune responses. VPAC1 is primarily expressed on T cells, whereas VPAC2 expression is induced by inflammation⁹². The anti-inflammatory effects of VIP are principally mediated via VPAC2 activation, which suppresses Th1 and Th17 functions and induces Th2 and regulatory T cells, resulting in immunosuppression⁸⁶. Therefore, the immunomodulatory actions of VIP expand its abilities to treat acute and chronic inflammatory and autoimmune diseases, including sepsis⁹³, multiple sclerosis⁹⁴, Crohn's disease⁹⁵, and type 1 diabetes⁹⁶.

VIP and inflammatory bowel diseases

VIP was proposed as a biomarker for inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a study reporting elevated VIP plasma concentrations during the active inflammatory disease phase⁹⁷. A recent study also reported that VIP content is higher in plasma and in ileal or colonic tissues resected from Crohn's disease or ulcerative colitis patients, respectively, than those from healthy subjects⁹⁸. Furthermore, the anti-inflammatory properties of VIP on Th1 immunity, which is involved in autoimmune diseases including IBD, suggest that VIP is involved in the pathogenesis of IBD and may be a therapeutic target. Nevertheless, the connection of VIP with animal models of colitis related to IBD has yet to be fully elucidated. The contribution of VIP towards the pathogenesis of dextran sulfate sodium (DSS)-induced and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced models of colitis in mice is controversial¹⁸.

The first report regarding VIP and colitis is that exogenous VIP improves TNBS-induced colitis in BALB/c mice, most likely via VPAC1 activation with anti-inflammatory and Th1–Th2 switching effects of VIP⁹⁹. Notably, higher doses of VIP likely aggravate the colitis⁹⁹. Later, another group reported that VIP administration by constant infusion enhanced the severity of TNBS-induced colitis¹⁰⁰. Subsequently, genetically modified animal models have been used to clarify the contributions

of endogenous VIP and its receptors to the pathogenesis of colitis. In the DSS-induced colitis model, VPAC1 KO mice are resistant to DSS-induced colitis, whereas colitis is exacerbated in VPAC2 KO mice; PKA inhibitors reverse the impairment of DSS colitis in VPAC2 KO mice, suggesting that enhanced VPAC1 activity in VPAC2 KO mice may aggravate DSS colitis⁵⁶ or is alternatively explained by the protective effects of VPAC2 during the development of DSS-induced colitis, since VPAC2 activation inhibits Th1 signals¹¹.

In VIP KO mice, DSS treatment had no effect on colitis in males, compared to wild-type males, whereas body weight loss and disease activity index in females was less frequently observed in VIP KO subjects⁴⁰, suggesting that VIP may have enhanced pro-inflammatory functions in females. Furthermore, male VIP KO mice or wild-type mice treated with a pan-VIP receptor antagonist (VIP-hybrid¹⁰¹) or the selective VPAC1 antagonist (PG97-269)¹⁵ are resistant to DSS-induced colitis with reduced levels of colonic inflammatory mediators and cytokines¹⁰², suggesting that VIP acts as a pro-inflammatory mediator. In TNBS-colitis, VIP KO mice are resistant to colitis with lower levels of TNF- α and IL-6¹⁰³. Similar resistant phenotypes are observed in a VIP KO with LPS-induced endotoxemia model, where LPS induced less mortality in VIP KO mice³⁶, and with the experimental autoimmune encephalomyelitis (EAE) model, where clinical scores were less in VIP KO mice¹⁰⁴. Nevertheless, VIP KO mice develop more severe colitis in the DNBS- or DSS-induced colitis models, which is rescued by exogenous VIP treatment³⁷. Most recently, a recombinant stable VIP analog (rVIPa) was reported to ameliorate TNBS-induced colonic injury and inflammation, effectively preserving intestinal mucosal barrier function in rats¹⁰⁵, most likely owing to increased stability of the VIP analog.

These discrepancies between anti-inflammatory and pro-inflammatory effects of VIP on chemically induced colitis models may reflect the differences between endogenous and exogenous effects of VIP due to dose effects and peptide stability in the tissues and circulation because VIP is rapidly degraded by dipeptidyl peptidase 4 (DPP4), similar to the incretins¹⁰⁶, and by other peptidases. Furthermore, genetic deficiency of VIP or VPAC irreversibly alters epithelial, neural, and immune responses during development. Another possibility is that targets of VIP may induce opposite effects on inflammation; VPAC2 activation on T cells shifts Th1 to Th2 differentiation as anti-inflammatory, whereas VPAC1 activation of epithelial cells increases anion and water secretion, with resultant diarrhea, which may affect the disease activity of colitis. VPAC2 activation of GI smooth muscles increases GI motility, whereas impaired motility in VIP KO or VPAC2 KO may affect GI transit, affecting the exposure time to luminal toxic chemicals such as DSS in drinking water. Therefore, cell-specific, conditional knockout will clarify these contradictory results.

VIP/PACAP and diabetes

The metabolic syndrome, including type 2 diabetes and obesity, is also a GI-related disorder, since insulinotropic hormones,

termed incretins, including GLP-1 and GIP, are secreted from enteroendocrine L and K cells, respectively. As mentioned above, vagal stimulation increases the release of PACAP and VIP in pancreatic islets, suggesting that PACAP and VIP modulate insulin secretion from β cells through the activation of cognate receptors.

Pancreatic islet β cells express PAC1 and VPAC2 with less VPAC1²⁸. Selective VPAC2 agonists are insulinotropic, similar to PACAP and GLP-1, amplifying glucose-induced insulin secretion¹⁰⁷. VIP KO mice exhibit elevated plasma glucose, insulin, and leptin levels with no change in islet mass³⁸, probably due to the compensatory effect of PACAP. In VPAC2 KO mice, glucose-induced insulin secretion is decreased with no change in glucose tolerance. VPAC1 KO mice show growth retardation, intestinal obstruction, and hypoglycemia⁴⁸, suggesting that VPAC1 is also involved in glucagon secretion, which counteracts the hypoglycemic effects of insulin. In isolated perfused pancreas, PAC1 KO mice exhibit a 50% reduction of the PACAP-induced insulin secretory response, whereas VIP-induced insulin secretion is unchanged¹⁰⁸, suggesting that the insulinotropic action of PACAP is partially mediated by PAC1. Therefore, VPAC2 agonists and PAC1 agonists are candidates for the therapy of type 2 diabetes.

VIP/PACAP and cancers

Human cancers including bladder, breast, colon, liver, lung, pancreatic, prostate, thyroid, and uterine cancers often overexpress VPAC1, whereas VPAC2 is limited in stromal tumors such as gastric leiomyomas, sarcomas, and neuroendocrine tumors¹⁰⁹. Since VPAC1 is normally expressed in the epithelium and VPAC2 in smooth muscle in the GI tract, these expression profiles may reflect their tumor expression with VPAC1 in adenocarcinoma and VPAC2 in stromal tumors. PAC1 is also expressed in diverse tumors including brain, breast, colon, lung, neuroendocrine, pancreas, pituitary, and prostate tumors as well as neuroblastomas¹¹⁰. This suggests that VIP/PACAP may affect tumor growth and differentiation. VIP and PACAP stimulate the growth of several cancer cell lines *in vitro*¹¹⁰, supporting this hypothesis.

Regarding the GI tract, colon cancer tissue overexpresses VPAC1: in 35% of well-differentiated, 65% of moderately differentiated, and 87% of poorly differentiated colon cancers¹¹¹, predicting tumor differentiation can be accomplished by measuring VPAC1 levels. Therefore, VPAC1 can be a target for anti-cancer drugs, since VPAC1 antagonists inhibit the growth of colonic cancer cell lines *in vitro*¹¹².

Overexpression of VPAC and PAC1 in tumors can be used for imaging and targeting tumors using radiolabeled VIP analogues. Clinical studies show that radiolabeled VIP analogues localize breast cancer, pancreatic cancer, intestinal adenocarcinomas, neuroendocrine tumors, and colorectal cancer using a combination of positron emission tomography (PET) and

computed tomography (CT) scans^{110,113}. Furthermore, VIP-conjugated nanoparticles have been developed to deliver the cytotoxic drug to tumor cells overexpressing VPAC¹¹⁴.

Therapeutic potential of VIP

Since VIP contributes to important physiological functions including anion secretion, the regulation of permeability of epithelial tight junctions, mucosal inflammation, glycemic control, Th1–Th2 balance, and tumor growth, VIP has been suggested to be a therapeutic target for diseases such as diarrhea⁵⁸, IBD⁹⁵, diabetes²⁸, autoimmune diseases¹¹⁵, neurodegenerative disorders¹¹⁶, lung disease^{117,118}, sarcoidosis¹¹⁹, and cancers¹¹⁴. Although VIP has well-studied anti-inflammatory and other therapeutic potential, VIP-based drug design has not been entirely successful because rapid degradation of the peptide limits its bioavailability and delivery. Furthermore, multiple cellular targets that bind VIP at high affinity may cause undesirable adverse effects. Therefore, synthesis of a stable VIP analog, or the targeted delivery of VIP or its analogs via nanoparticles are desirable options.

Recent advances in the field include the synthesis of stable analogs such as lipophilic or peptide VIP derivatives that mimic the activity of native VIP¹²⁰. Another strategy is VIP self-associated with sterically stabilized micelles, which protects

VIP from degradation and inactivation¹¹⁵. Injection of VIP-induced regulatory dendritic cells ameliorates TNBS-induced colitis models in mice⁹⁵. VIP gene transfer using lentivirus is also useful to induce immunosuppression in the murine arthritis model¹²¹. Finally, VIP-tagged nanoparticles may be a useful strategy for selective drug delivery to VPAC-overexpressing tumor cells and immune cells^{114,122}.

Summary and conclusions

Since its discovery in 1970, VIP has been studied in numerous organ systems including the gastrointestinal, respiratory, cardiovascular, immune, endocrine, and central and peripheral nervous systems, where it exerts numerous important effects (Figure 2). Nevertheless, owing to its protean and widespread effects on numerous organ systems combined with its inherent instability, VIP has been challenging to clearly discern and analyze regarding its influence on isolated pathophysiological functions. Specifically, in the gut, VIP has therapeutic potential for a variety of inflammatory disorders such as IBD. The recent progress of VIP-related medicine is aimed at improvement of its stability, selectivity, and efficacy with reduced adverse effects. In order to make optimal therapeutic use of, it is essential to further study its localization and actions, working towards selective targeting or individual effects.

Vasoactive intestinal peptide affects multiple organ systems

Circulatory system

- Regulates cardiac contractility [3]
- Coronary & systemic vasodilation [3]
- Increases glycogenolysis and lowers arterial blood pressure [3]
- Increases cardiac output [3]

Endocrine system

- Increases insulin and glucagon secretion [28]
- Increases blood flow in thyroid but has no effect on hormone levels [52]

Respiratory system

- Relaxes airway and pulmonary vascular smooth muscle [117]
- Inhibits airway and pulmonary vascular smooth muscle proliferation [117]
- Bronchodilation [11]

Central nervous system

- Regulates circadian rhythms [7]
- Noncholinergic relaxation of vascular and nonvascular smooth muscle [11]
- Increases neuronal survival and regulates glycogen metabolism in the cerebral cortex [18]
- Promotion of embryonic growth and brain development [54]

Immune system

- Macrophage-deactivating factor [11]
- Regulates the differentiation of CD4⁺ T (T helper [Th]) cells [18]
- Anti-inflammatory [86]
- Defense mechanism against septic shock [93]

Digestive system

- Increases the secretion and inhibits the absorption of intestinal luminal fluid [24]
- Relaxes smooth muscle and mediates distention-induced reflexes [87]
- Decreases intestinal paracellular permeability [82]
- Increases epithelial cell proliferation [40]
- Releases pancreatic enzymes [64]

Figure 2. Broad multiple functions of vasoactive intestinal peptide in various organs. Number in parenthesis represents the corresponding reference number.

References



1. Said SI, Mutt V: **Polypeptide with broad biological activity: isolation from small intestine.** *Science*. 1970; **169**(3951): 1217–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Gronenborn AM, Bovermann G, Clore GM: **A ¹H-NMR study of the solution conformation of secretin. Resonance assignment and secondary structure.** *FEBS Lett*. 1987; **215**(1): 88–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Henning RJ, Sawmiller DR: **Vasoactive intestinal peptide: cardiovascular effects.** *Cardiovasc Res*. 2001; **49**(1): 27–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Said SI: **Vasoactive intestinal peptide.** *J Endocrinol Invest*. 1986; **9**(2): 191–200.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Umetsu Y, Tenno T, Goda N, *et al.*: **Structural difference of vasoactive intestinal peptide in two distinct membrane-mimicking environments.** *Biochim Biophys Acta*. 2011; **1814**(5): 724–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Tsukada T, Horovitch SJ, Montminy MR, *et al.*: **Structure of the human vasoactive intestinal polypeptide gene.** *DNA*. 1985; **4**(4): 293–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Fahrenkrug J: **Transmitter role of vasoactive intestinal peptide.** *Pharmacol Toxicol*. 1993; **72**(6): 354–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Said SI, Mutt V: **Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon.** *Eur J Biochem*. 1972; **28**(2): 199–204.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Bayliss WM, Starling EH: **The mechanism of pancreatic secretion.** *J Physiol*. 1902; **28**(5): 325–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Said S, Rosenberg RN: **Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue.** *Science*. 1976; **192**(4242): 907–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Delgado M, Pozo D, Ganea D: **The significance of vasoactive intestinal peptide in immunomodulation.** *Pharmacol Rev*. 2004; **56**(2): 249–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Bloom SR, Christofides ND, Delamarter J, *et al.*: **Diarrhoea in vipoma patients associated with cosecretion of a second active peptide (peptide histidine isoleucine) explained by single coding gene.** *Lancet*. 1983; **2**(8360): 1163–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Aimi Y, Kimura H, Kinoshita T, *et al.*: **Histochemical localization of nitric oxide synthase in rat enteric nervous system.** *Neuroscience*. 1993; **53**(2): 553–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Itoh N, Obata K, Yanaihara N, *et al.*: **Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27.** *Nature*. 1983; **304**(5926): 547–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Gourilet P, De Neef P, Cnudde J, *et al.*: **In vitro properties of a high affinity selective antagonist of the VIP₁ receptor.** *Peptides*. 1997; **18**(10): 1555–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Pisegna JR, Wank SA: **Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.** *Proc Natl Acad Sci U S A*. 1993; **90**(13): 6345–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Harmar AJ, Fahrenkrug J, Gozes I, *et al.*: **Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1.** *Br J Pharmacol*. 2012; **166**(1): 4–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Padua D, Vu JP, Germano PM, *et al.*: **The Role of Neuropeptides in Mouse Models of Colitis.** *J Mol Neurosci*. 2016; **59**(2): 203–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Sherwood NM, Krueckl SL, McRory JE: **The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily.** *Endocr Rev*. 2000; **21**(6): 619–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Larsson LI, Fahrenkrug J, Schaffalitzky De Muckadell O, *et al.*: **Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral neurons.** *Proc Natl Acad Sci U S A*. 1976; **73**(9): 3197–200.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Costa M, Furness JB: **The origins, pathways and terminations of neurons with VIP-like immunoreactivity in the guinea-pig small intestine.** *Neuroscience*. 1983; **8**(4): 665–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Manaka H, Manaka Y, Kostolanska F, *et al.*: **Release of VIP and substance P from isolated perfused canine ileum.** *Am J Physiol*. 1989; **257**(2 Pt 1): G182–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Fang X, Hu HZ, Gao N, *et al.*: **Neurogenic secretion mediated by the purinergic P2Y₂ receptor in guinea-pig small intestine.** *Eur J Pharmacol*. 2006; **536**(1–2): 113–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Eklund S, Fahrenkrug J, Jodal M, *et al.*: **Vasoactive intestinal polypeptide, 5-hydroxytryptamine and reflex hyperaemia in the small intestine of the cat.** *J Physiol*. 1980; **302**: 549–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Brunsson I, Fahrenkrug J, Jodal M, *et al.*: **Substance P effects on blood flow, fluid transport and vasoactive intestinal polypeptide release in the feline small intestine.** *J Physiol*. 1995; **483**(Pt 3): 727–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Guan X, Karpen HE, Stephens J, *et al.*: **GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow.** *Gastroenterology*. 2006; **130**(1): 150–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
27.  Kuwahara A, Kuwahara Y, Kato I, *et al.*: **Xenin-25 induces anion secretion by activating noncholinergic secretomotor neurons in the rat ileum.** *Am J Physiol Gastrointest Liver Physiol*. 2019; **316**(6): G785–G796.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
28. Sanlioglu AD, Karacay B, Balci MK, *et al.*: **Therapeutic potential of VIP vs PACAP in diabetes.** *J Mol Endocrinol*. 2012; **49**(3): R157–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Porter AJ, Wattoo DA, Brookes SJ, *et al.*: **The neurochemical coding and projections of circular muscle motor neurons in the human colon.** *Gastroenterology*. 1997; **113**(6): 1916–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Leceta J, Martinez MC, Delgado M, *et al.*: **Lymphoid cell subpopulations containing vasoactive intestinal peptide in the rat.** *Peptides*. 1994; **15**(5): 791–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Delgado M, Ganea D: **Cutting edge: is vasoactive intestinal peptide a type 2 cytokine?** *J Immunol*. 2001; **166**(5): 2907–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Martinez C, Delgado M, Abad C, *et al.*: **Regulation of VIP production and secretion by murine lymphocytes.** *J Neuroimmunol*. 1999; **93**(1–2): 126–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Havel PJ, Dunning BE, Verchere CB, *et al.*: **Evidence that vasoactive intestinal polypeptide is a parasympathetic neurotransmitter in the endocrine pancreas in dogs.** *Regul Pept*. 1997; **71**(3): 163–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Yada T, Sakurada M, Ishihara H, *et al.*: **Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats.** *J Physiol*. 1997; **505**(Pt 2): 319–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Colwell CS, Michel S, Itri J, *et al.*: **Disrupted circadian rhythms in VIP- and PHI-deficient mice.** *Am J Physiol Regul Integr Comp Physiol*. 2003; **285**(5): R939–R949.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Abad C, Tan YV, Cheung-Lau G, *et al.*: **VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses.** *PLoS One*. 2012; **7**(5): e36922.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Wu X, Conlin VS, Morampudi V, *et al.*: **Vasoactive intestinal polypeptide promotes intestinal barrier homeostasis and protection against colitis in mice.** *PLoS One*. 2015; **10**(5): e0125225.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Martin B, Shin YK, White CM, *et al.*: **Vasoactive intestinal peptide-null mice demonstrate enhanced sweet taste preference, dysglycemia, and reduced taste bud leptin receptor expression.** *Diabetes*. 2010; **59**(5): 1143–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Lelievre V, Favrais G, Abad C, *et al.*: **Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease.** *Peptides*. 2007; **28**(9): 1688–99.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Yusta B, Holland D, Waschek JA, *et al.*: **Intestintrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice.** *Endocrinology*. 2012; **153**(6): 2623–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Fung C, Unterwieser P, Parry LJ, *et al.*: **VPAC₂ receptors regulate intestinal secretion and muscle contractility by activating cholinergic neurons in guinea pig jejunum.** *Am J Physiol Gastrointest Liver Physiol*. 2014; **306**(9): G748–G758.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Keita AV, Carlsson AH, Cigéhn M, *et al.*: **Vasoactive intestinal polypeptide regulates barrier function via mast cells in human intestinal follicle-associated epithelium and during stress in rats.** *Neurogastroenterol Motil*. 2013; **25**(6): e406–e417.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Groneberg DA, Rabe KF, Fischer A: **Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.** *Eur J Pharmacol*. 2006; **533**(1–3): 182–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
44.  Jayawardena D, Guzman G, Gill RK, *et al.*: **Expression and localization of**

- VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.** *Am J Physiol Gastrointest Liver Physiol.* 2017; **313**(1): G16–G25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
45. Kuwahara A, Kuwahara Y, Mochizuki T, *et al.*: **Action of pituitary adenylate cyclase-activating polypeptide on ion transport in guinea pig distal colon.** *Am J Physiol.* 1993; **264**(3 Pt 1): G433–G441.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Seidler U, Blumenstein I, Kretz A, *et al.*: **A functional CFTR protein is required for mouse intestinal cAMP-, cGMP- and Ca²⁺-dependent HCO₃⁻ secretion.** *J Physiol.* 1997; **505**(Pt 2): 411–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Shanahan F, Denburg JA, Fox J, *et al.*: **Mast cell heterogeneity: effects of neuroenteric peptides on histamine release.** *J Immunol.* 1985; **135**(2): 1331–7.
[PubMed Abstract](#)
48. Fabricius D, Karacay B, Shutt D, *et al.*: **Characterization of intestinal and pancreatic dysfunction in VPAC1-null mutant mouse.** *Pancreas.* 2011; **40**(6): 861–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Reubi JC: **In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications.** *Ann NY Acad Sci.* 2000; **921**: 1–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Harmar AJ, Sheward WJ, Morrison CF, *et al.*: **Distribution of the VPAC₂ receptor in peripheral tissues of the mouse.** *Endocrinology.* 2004; **145**(3): 1203–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Fahrenkrug J, Hannibal J: **Localisation of the neuropeptide PACAP and its receptors in the rat parathyroid and thyroid glands.** *Gen Comp Endocrinol.* 2011; **171**(1): 105–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Huffman L, Hedge GA: **Effects of vasoactive intestinal peptide on thyroid blood flow and circulating thyroid hormone levels in the rat.** *Endocrinology.* 1986; **118**(2): 550–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Inagaki N, Yoshida H, Mizuta M, *et al.*: **Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells.** *Proc Natl Acad Sci U S A.* 1994; **91**(7): 2679–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Asnicar MA, Köster A, Heiman ML, *et al.*: **Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate.** *Endocrinology.* 2002; **143**(10): 3994–4006.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Bechtold DA, Brown TM, Luckman SM, *et al.*: **Metabolic rhythm abnormalities in mice lacking VIP-VPAC₂ signaling.** *Am J Physiol Regul Integr Comp Physiol.* 2008; **294**(2): R344–R351.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. **F** Yadav M, Huang MC, Goetzl EJ: **VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.** *Cell Immunol.* 2011; **267**(2): 124–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
57. Azuma YT, Hagi K, Shintani N, *et al.*: **PACAP provides colonic protection against dextran sodium sulfate induced colitis.** *J Cell Physiol.* 2008; **216**(1): 111–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Banks MR, Farthing MJ, Robberecht P, *et al.*: **Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine.** *Br J Pharmacol.* 2005; **144**(7): 994–1001.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Schwartz CJ, Kimberg DV, Sheerin HE, *et al.*: **Vasoactive intestinal peptide stimulation of adenylate cyclase and active electrolyte secretion in intestinal mucosa.** *J Clin Invest.* 1974; **54**(3): 536–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. O'Grady SM, Wolters PJ, Hildebrand K, *et al.*: **Regulation of ion transport in porcine gallbladder: effects of VIP and norepinephrine.** *Am J Physiol.* 1989; **257**(1 Pt 1): C52–C57.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Fahrenkrug J, Schaffalitzky de Muckadell OB, Holst JJ, *et al.*: **Vasoactive intestinal polypeptide in vagally mediated pancreatic secretion of fluid and HCO₃. Am J Physiol.** 1979; **237**(6): E535–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Ito T, Igarashi H, Jensen RT: **Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.** *Best Pract Res Clin Gastroenterol.* 2012; **26**(6): 737–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Nakayama S, Yokote T, Kobayashi K, *et al.*: **VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome.** *Endocrine.* 2009; **35**(2): 143–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Ito T, Hou W, Katsuno T, *et al.*: **Rat and guinea pig pancreatic acini possess both VIP₁ and VIP₂ receptors, which mediate enzyme secretion.** *Am J Physiol Gastrointest Liver Physiol.* 2000; **278**(1): G64–G74.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Eklund S, Jodal M, Lundgren O, *et al.*: **Effects of vasoactive intestinal polypeptide on blood flow, motility and fluid transport in the gastrointestinal tract of the cat.** *Acta Physiol Scand.* 1979; **105**(4): 461–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Holzer P, Guth PH: **Neuropeptide control of rat gastric mucosal blood flow. Increase by calcitonin gene-related peptide and vasoactive intestinal polypeptide, but not substance P and neurokinin A.** *Circ Res.* 1991; **68**(1): 100–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Nylander O, Hallgren A, Holm L: **Duodenal mucosal alkaline secretion, permeability, and blood flow.** *Am J Physiol.* 1993; **265**(6 Pt 1): G1029–G1038.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Grant S, Lutz EM, McPhaden AR, *et al.*: **Location and function of VPAC₁, VPAC₂ and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries.** *J Cereb Blood Flow Metab.* 2005; **26**(1): 58–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Sjöqvist A, Fahrenkrug J, Hemlin M, *et al.*: **Effects of intra-arterially infused adenosine triphosphate (ATP) on release of vasoactive intestinal polypeptide (VIP) from the gastrointestinal tract of the cat.** *Acta Physiol Scand.* 1985; **125**(4): 693–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. von der Weid PY, Rehal S, Dyrda P, *et al.*: **Mechanisms of VIP-induced inhibition of the lymphatic vessel pump.** *J Physiol.* 2012; **590**(11): 2677–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Teng B, Murthy KS, Kuemmerle JF, *et al.*: **Selective expression of vasoactive intestinal peptide (VIP)₁/pituitary adenylate cyclase-activating polypeptide (PACAP)₃ receptors in rabbit and guinea pig gastric and tenia coli smooth muscle cells.** *Regul Pept.* 1998; **77**(1–3): 127–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Severi C, Tattoli I, Corleto VD, *et al.*: **Vasoactive intestinal peptide receptor subtypes and signalling pathways involved in relaxation of human stomach.** *Neurogastroenterol Motil.* 2006; **18**(11): 1009–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. Robberecht P, De Neef P, Lefebvre RA: **Influence of selective VIP receptor agonists in the rat gastric fundus.** *Eur J Pharmacol.* 1998; **359**(1): 77–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Mukai K, Satoh Y, Fujita A, *et al.*: **PAC1 receptor-mediated relaxation of longitudinal muscle of the mouse proximal colon.** *Jpn J Pharmacol.* 2002; **90**(1): 97–100.
[PubMed Abstract](#) | [Publisher Full Text](#)
75. Konturek SJ, Dembiński A, Thor P, *et al.*: **Comparison of vasoactive intestinal peptide (VIP) and secretin in gastric secretion and mucosal blood flow.** *Pflügers Arch.* 1976; **361**(2): 175–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Villar HV, Fender HR, Rayford PL, *et al.*: **Suppression of gastrin release and gastric secretion by gastric inhibitory polypeptide (GIP) and vasoactive intestinal polypeptide (VIP).** *Ann Surg.* 1976; **184**(1): 97–102.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Mungan Z, Hammer RA, Akarca US, *et al.*: **Effect of PACAP on gastric acid secretion in rats.** *Peptides.* 1995; **16**(6): 1051–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Zeng N, Athmann C, Kang T, *et al.*: **PACAP type I receptor activation regulates ECL cells and gastric acid secretion.** *J Clin Invest.* 1999; **104**(10): 1383–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. **F** Hunne B, Stebbing MJ, McQuade RM, *et al.*: **Distributions and relationships of chemically defined enteroendocrine cells in the rat gastric mucosa.** *Cell Tissue Res.* 2019; **185**: 37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
80. Miampamba M, Germano PM, Ari S, *et al.*: **Expression of pituitary adenylate cyclase-activating polypeptide and PACAP type 1 receptor in the rat gastric and colonic myenteric neurons.** *Regul Pept.* 2002; **105**(3): 145–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. Egerod KL, Engelstoft MS, Lund ML, *et al.*: **Transcriptional and Functional Characterization of the G Protein-Coupled Receptor Repertoire of Gastric Somatostatin Cells.** *Endocrinology.* 2015; **156**(11): 3909–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Neunlist M, Toumi F, Oreschkova T, *et al.*: **Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways.** *Am J Physiol Gastrointest Liver Physiol.* 2003; **285**(5): G1028–G1036.
[PubMed Abstract](#) | [Publisher Full Text](#)
83. **F** Conlin VS, Wu X, Nguyen C, *et al.*: **Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis.** *Am J Physiol Gastrointest Liver Physiol.* 2009; **297**(4): G735–G750.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
84. **F** Clayburgh DR, Barrett TA, Tang Y, *et al.*: **Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo.** *J Clin Invest.* 2005; **115**(10): 2702–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
85. Delgado M, Pozo D, Martinez C, *et al.*: **Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies.** *J Immunol.* 1999; **162**(4): 2358–67.
[PubMed Abstract](#)
86. **F** Abad C, Tan YV: **Immunomodulatory Roles of PACAP and VIP: Lessons**

- from Knockout Mice. *J Mol Neurosci*. 2018; **66**(1): 102–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
87. Sohn W, Lee OY, Lee SP, *et al.*: Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea. *Scand J Gastroenterol*. 2014; **49**(1): 43–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
88. F Bednarska O, Walter SA, Casado-Bedmar M, *et al.*: Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome. *Gastroenterology*. 2017; **153**(4): 948–960.e3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
89. Taché Y, Million M: Role of Corticotropin-releasing Factor Signaling in Stress-related Alterations of Colonic Motility and Hyperalgesia. *J Neurogastroenterol Motil*. 2015; **21**(1): 8–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. F Yakabi S, Wang L, Karasawa H, *et al.*: VIP is involved in peripheral CRF-induced stimulation of propulsive colonic motor function and diarrhea in male rats. *Am J Physiol Gastrointest Liver Physiol*. 2018; **314**(5): G610–G622.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
91. F Ahluwalia B, Magnusson MK, Öhman L: Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad. *Scand J Gastroenterol*. 2017; **52**(11): 1185–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
92. Delgado M, Gonzalez-Rey E, Ganea D: VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. *FASEB J*. 2004; **18**(12): 1453–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Delgado M, Gomariz RP, Martinez C, *et al.*: Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxin shock. *Eur J Immunol*. 2000; **30**(11): 3236–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Cobo M, Anderson P, Benabdellah K, *et al.*: Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis. *Cell Transplant*. 2013; **22**(5): 839–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
95. F Gonzalez-Rey E, Delgado M: Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. *Gastroenterology*. 2006; **131**(16): 1799–811.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
96. Jimeno R, Gomariz RP, Gutiérrez-Cañas I, *et al.*: New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. *Immunol Cell Biol*. 2010; **88**(7): 734–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Duffy LC, Zielezny MA, Riepenhoff-Talty M, *et al.*: Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease. *Dig Dis Sci*. 1989; **34**(10): 1528–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
98. F Casado-Bedmar M, Heil SDS, Myrelić P, *et al.*: Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis. *Neurogastroenterol Motil*. 2019; **31**(3): e13503.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
99. Abad C, Martinez C, Juarranz MG, *et al.*: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. *Gastroenterology*. 2003; **124**(4): 961–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. Newman R, Cuan N, Hampartzoumian T, *et al.*: Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. *Clin Exp Immunol*. 2005; **139**(3): 411–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
101. Moody TW, Jensen RT, Fridkin M, *et al.*: (N-stearyl, norleucine¹⁷)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. *J Mol Neurosci*. 2002; **18**(1–2): 29–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Vu JP, Million M, Larauche M, *et al.*: Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice. *J Mol Neurosci*. 2014; **52**(1): 37–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
103. Abad C, Cheung-Lau G, Couët-Monvoisin AC, *et al.*: Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis. *Neuroimmunomodulation*. 2015; **22**(3): 203–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Abad C, Tan YV, Lopez R, *et al.*: Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci U S A*. 2010; **107**(45): 19555–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
105. F Xu CL, Guo Y, Qiao L, *et al.*: Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats. *World J Gastroenterol*. 2018; **24**(6): 706–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
106. Lambeir AM, Durinx C, Scharpé S, *et al.*: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. *Crit Rev Clin Lab Sci*. 2008; **40**(3): 209–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
107. Tsutsumi M, Claus TH, Liang Y, *et al.*: A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. *Diabetes*. 2002; **51**(5): 1453–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
108. Jamen F, Persson K, Bertrand G, *et al.*: PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. *J Clin Invest*. 2000; **105**(9): 1307–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
109. Reubi JC, Läderach U, Waser B, *et al.*: Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. *Cancer Res*. 2000; **60**(11): 3105–12.
[PubMed Abstract](#)
110. F Moody TW, Nuche-Berenguer B, Jensen RT: Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. *Curr Opin Endocrinol Diabetes Obes*. 2016; **23**(1): 38–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
111. Liu S, Zeng Y, Li Y, *et al.*: VPAC1 overexpression is associated with poor differentiation in colon cancer. *Tumor Biol*. 2014; **35**(7): 6397–404.
[PubMed Abstract](#) | [Publisher Full Text](#)
112. Levy A, Gal R, Granoth R, *et al.*: In vitro and in vivo treatment of colon cancer by VIP antagonists. *Regul Pept*. 2002; **109**(1–3): 127–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
113. Tang B, Yong X, Xie R, *et al.*: Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review). *Int J Oncol*. 2014; **44**(4): 1023–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
114. Gülçür E, Taqi M, Khaja F, *et al.*: Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells. *Drug Deliv Transl Res*. 2013; **3**(6): 562–574.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Sethi V, Rubinstein I, Kuzmis A, *et al.*: Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis. *Mol Pharm*. 2013; **10**(2): 728–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
116. Waschek JA: VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. *Br J Pharmacol*. 2013; **169**(3): 512–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
117. Said SI, Hamidi SA, Dickman KG, *et al.*: Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. *Circulation*. 2007; **115**(10): 1260–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
118. Wu D, Lee D, Sung YK: Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. *Respir Res*. 2011; **12**: 45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
119. Prasse A, Zissel G, Lützen N, *et al.*: Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. *Am J Respir Crit Care Med*. 2010; **182**(4): 540–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
120. Gozes I, Bardea A, Reshef A, *et al.*: Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. *Proc Natl Acad Sci U S A*. 1996; **93**(1): 427–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
121. Delgado M, Toscano MG, Benabdellah K, *et al.*: In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. *Arthritis Rheum*. 2008; **58**(4): 1026–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
122. Klippstein R, Pozo D: Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery. *Adv Protein Chem Struct Biol*. 2015; **98**: 145–68.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status: 

Editorial Note on the Review Process

F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

- Pradeep Dudeja**
Division of Gastroenterology and Hepatology, Department of Medicine, Jesse Brown VA Medical Center, University of Illinois at Chicago, Chicago, IL, USA
Competing Interests: No competing interests were disclosed.
- Michael Camilleri**
Clinical Enteric Neurosciences Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, USA
Competing Interests: No competing interests were disclosed.
- Peter Holzer**
Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria
Competing Interests: No competing interests were disclosed.
- Mario Delgado**
Institute of Parasitology and Biomedicine Lopez-Neyra, Consejo Superior Investigaciones Cientificas, Granada, 18016, Spain
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research